http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy
-
FDA approves Greenwich LifeSciences commercial GP2 for FLAMINGO-01 trial
-
Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01
-
Greenwich LifeSciences extends director lock-up to September 2026
-
Greenwich LifeSciences Extends Lock-up of Directors and Officers to September 30, 2026
-
Greenwich LifeSciences reports progress on FLAMINGO-01 breast cancer trial
-
Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy
-
Greenwich LifeSciences reports 80% recurrence reduction in cancer trial
-
Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01
-
Greenwich LifeSciences completes enrollment in open label arm of phase III trial
-
Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01
-
Greenwich LifeSciences screens over 1,000 patients in phase III trial
-
Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date
-
Greenwich LifeSciences adds Austria to Phase III breast cancer trial
-
Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial
-
Greenwich LifeSciences expands breast cancer trial to Belgium
-
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium
-
Greenwich LifeSciences expands FLAMINGO-01 trial to Portugal
-
Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial
-
Greenwich LifeSciences expands breast cancer trial to Ireland
-
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland
-
Greenwich LifeSciences gets FDA fast track status for breast cancer drug
-
Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation
-
Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences
-
Greenwich LifeSciences builds internal clinical operations team
-
Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team
-
Greenwich LifeSciences expands breast cancer trial to Romania
-
Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania
-
Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events
-
Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events
-
Greenwich LifeSciences Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
-
Greenwich LifeSciences (GLSI) Provides Global Update on FLAMINGO-01
-
Greenwich LifeSciences Provides Global Update on FLAMINGO-01
-
Greenwich LifeSciences (GLSI) Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial
-
Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial
-
Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026
-
Greenwich LifeSciences (GLSI) Provides Update on Open Label Safety Data from FLAMINGO-01
-
Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01
-
Greenwich LifeSciences (GLSI) Provides Update on Open Label HLA Data from FLAMINGO-01
-
Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01
-
Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe
-
Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland
-
Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01
-
Greenwich LifeSciences (GLSI) Provides Update on Commercial Manufacturing
-
Greenwich LifeSciences Provides Update on Commercial Manufacturing
-
Greenwich LifeSciences (GLSI) Announces Partnership with GBG in Germany for Flamingo-01
-
Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01
-
Greenwich LifeSciences Partners with Unicancer Expanding Flamingo-01 into France
-
Greenwich LifeSciences Partners with GIM in Italy
-
Greenwich LifeSciences Provides Update on Corporate Events

